ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2018

Jul 26, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2018-07-26

Reporting Person: Schuyler Kevin (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	50929	Direct
Common Stock	3042	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant	$.0054	2021-12-31	Common Stock (1010)		Direct
Warrant	$7.63	2031-12-31	Common Stock (8649)		Direct
Warrant	$.0054	2021-12-31	Common Stock (1963)		Indirect
Warrant	$7.63	2031-12-31	Common Stock (1172)		Indirect
Convertible Note	$0.44		Common Stock (82461)		Direct
Stock Option	$5.7	2027-06-30	Common Stock (5580)		Direct

Footnotes

F1: 82,461 shares to be issued to upon consummation of this offering upon automatic conversion of a convertible note in the principal amount of $27,550, at a conversion price of $0.44 per share.

F2: The option has an exercise price of $5.70 per share and vests as to 1/6th of the grant on January 1, 2018 with the remaining shares vesting 1/36th on the first day of each month over the remaining 30 months.